MRK Stock Outlook 2026: Merck's Keytruda Clock Is Ticking—Here's What Comes Next

Keytruda’s 2028 loss of exclusivity is not a hidden risk—it’s the most widely discussed pharmaceutical event in the industry right now. Yet Merck trades at $112.30, only 10% off its 52-week high of $125.14 (May 2026, per stockanalysis.com), and carries a Buy consensus from 17 analysts with a $125.29 target. The market is not pricing in catastrophe; it’s pricing in a managed transition.

Whether that optimism is warranted depends on two things: how steeply Keytruda revenue falls post-2028, and how fast Winrevair and the rest of Merck’s pipeline can replace it. This analysis works through both.

Keytruda’s Dominance: The Drug That Built Modern Merck

Pembrolizumab—sold as Keytruda—is arguably the most successful oncology drug in history by cumulative revenue. A PD-1 checkpoint inhibitor, it has secured FDA approvals across dozens of cancer indications: non-small cell lung cancer, melanoma, head and neck cancers, urothelial cancer, colorectal cancer, and more. Every additional approval adds to the revenue base that Merck must eventually replace.

That the company is growing revenue even as it stares down the LOE clock says something real about Keytruda’s commercial momentum. Q1 2026 revenue of $16.3B was up 5% year-over-year—with Keytruda as the primary driver. FY2025 revenue came in at $65.0B, and TTM (through Q1 2026) stands at $65.8B.

The 2028 LOE will trigger biosimilar competition. Unlike small-molecule generics, monoclonal antibody biosimilars don’t achieve 80–90% market penetration overnight. The Humira (adalimumab) case study—where biosimilars launched in 2023 and captured meaningful share within 18 months—is instructive but not directly analogous. Keytruda’s clinical complexity and physician familiarity create some switching friction. Still, material revenue pressure by 2029–2030 is the base case.

The Q1 2026 Nuance: One-Time Charge, Not Operational Deterioration

Merck’s Q1 2026 headline results included a reported net loss, driven by approximately a $9 billion charge related to the Sedera acquisition. This is critical to understand: the operational business—Keytruda growth, animal health stability, Winrevair launch—performed well.

Investors who misread this as a sign of fundamental deterioration would be making an error. The charge reflects balance sheet accounting, not competitive setbacks. On an adjusted basis, Merck’s Q1 operational metrics were consistent with the growth trajectory management outlined.

Winrevair: The Best Bet on What Comes After Keytruda

Sotatercept (Winrevair) represents Merck’s clearest claim on post-Keytruda relevance. FDA-approved in 2024 for pulmonary arterial hypertension, it attacks the disease through a distinct mechanism—inhibiting activin signaling to reduce abnormal vascular smooth muscle cell proliferation—rather than just managing pulmonary pressures pharmacologically.

PAH is a severe, progressive disease with high unmet need. Existing drugs slow progression; Winrevair’s pivotal trial data showed actual improvements in exercise capacity and disease markers, not just stabilization. The addressable market is smaller than Keytruda’s (PAH is an orphan-adjacent indication), but the pricing power in rare disease with strong clinical differentiation is substantial.

For Merck, Winrevair’s success trajectory over the next 24 months will be the most important data point for investors trying to assess the post-LOE story.

Animal Health: Merck’s Quiet Ballast

Merck Animal Health is routinely overlooked in the analysis of MRK. It shouldn’t be. Products like Bravecto (fluralaner, anti-parasitic for companion animals) and Credelio (lotilaner) are market leaders in the high-growth companion animal space.

Why it matters for stock analysis:

1. Low volatility: Animal health revenue is less sensitive to drug pricing regulation than human pharma
2. IRA-exempt: Price negotiation provisions don’t apply to veterinary products
3. Structural tailwind: Pet ownership and premiumization of pet care have driven durable growth in this segment globally

It’s not going to replace Keytruda’s revenue, but it provides a stable, growing earnings floor that supports the dividend and limits downside in the bear case.

Valuation: Premium Justified by Transition Quality

Metric	Merck (MRK)	Sector Median
Price (May 2026)	$112.30	—
P/E (TTM)	31.4x	~25x
Forward P/E	18.4x	~20x
Dividend Yield	3.0%	~2.5%
Market Cap	$277.4B	—
52-Week Range	$73.31–$125.14	—
Consensus Target	$125.29	—

The TTM P/E of 31.4x is distorted by the Sedera write-down. The forward P/E of 18.4x is the more meaningful figure—and it’s actually below the sector median of ~20x. That’s a counterintuitive valuation story: a drug company with the world’s best-selling oncology franchise trading at a discount to forward earnings.

The discount reflects Keytruda LOE risk and IRA uncertainty. But it also creates an opportunity if the pipeline execution holds.

The IRA: A Known Unknown for Keytruda

The Inflation Reduction Act’s drug price negotiation provisions apply to drugs with the highest Medicare Part D and Part B spending. Keytruda’s position as one of the top revenue-generating drugs in Medicare makes it a natural candidate for negotiation.

The negotiated price discount, when it takes effect, will reduce Merck’s net revenue from Medicare patients on Keytruda. This headwind compounds the LOE pressure. Management has not provided specific guidance on the quantum of impact—and won’t until negotiations conclude.

For modeling purposes, conservative assumptions should layer in both LOE-driven volume erosion and IRA-driven price pressure from 2028 onward. The combined effect in a bear case could be severe. In a base case, the pace of Winrevair and pipeline approvals determines how quickly the gap is bridged.

Bull / Base / Bear: 12-Month Price Targets

Scenario	Key Assumptions	12-Month Target	vs. Current
Bull	Winrevair blockbuster trajectory, new pipeline approvals, Keytruda indications expand	$140	+24.7%
Base	Guidance delivered, Keytruda stable, Winrevair builds launch momentum	$125	+11.3%
Bear	Keytruda pricing pressure accelerates pre-LOE, key pipeline miss	$90	-19.9%

The base case aligns with the consensus target of $125.29. The bull case requires Winrevair to demonstrate blockbuster-level commercial traction in its first two years—possible, not guaranteed. The bear case is a re-rating event triggered by early Keytruda revenue erosion (IRA settlement or unexpected market share loss to competing checkpoint inhibitors).

Tax Considerations for US Investors

IRA and 401(k): Merck’s 3% yield is decent but not high enough to make the tax-location decision critical. Dividend income in a taxable account is qualified and taxed at 15–20%. Inside a traditional IRA, you defer tax but lose the qualified rate preference. Given MRK’s dual identity as a growth stock (pre-2028) and income stock, holding in a taxable account and managing gains actively makes sense for most investors.

Roth conversion window: If you hold MRK in a traditional IRA and anticipate the stock appreciating toward $140+ in a bull case, converting to Roth now locks in the tax liability at current values. This is particularly attractive for investors in lower income years.

401(k) for long-term holders: If your 401(k) offers a broad healthcare or S&P 500 fund with MRK exposure, the simplicity of tax-deferred compounding beats tactical tax optimization for most long-term holders. The Keytruda LOE is three years away—plenty of compounding runway.

Capital gains timing: MRK’s 52-week low was $73.31. Investors who bought near those lows are sitting on ~50% gains. A 2026 sale captures those gains in the current tax year; consider whether your total capital gains picture for the year makes this advantageous or costly.

Competitor Landscape

Company	Ticker	P/E	Div. Yield	Key Risk
Merck	MRK	31.4x	3.0%	Keytruda 2028 LOE
Pfizer	PFE	20.2x	6.5%	Eliquis cliff, obesity race
Bristol-Myers Squibb	BMY	~8x	~5.5%	Multiple patent cliffs
AstraZeneca	AZN	~30x	~2%	China exposure
Amgen	AMGN	~17x	~3.5%	Biosimilar competition

Related: Pfizer (PFE) Stock Outlook 2026 | Bristol-Myers Squibb Stock Outlook 2026 | Amgen Stock Outlook 2026

The Verdict

Merck is in the final innings of Keytruda’s peak commercial run, and management knows it. The response—Winrevair, Terns acquisition, HIV portfolio (IDVYNSO), Google Cloud AI collaboration—reflects a company that is not standing still.

The base case for the next 12 months is compelling: 11% price upside to consensus + 3% dividend = ~14% total return if execution holds. The risk is that the market begins pricing in post-2028 deterioration earlier than expected, compressing the multiple before the LOE even arrives.

For investors with a 1–2 year time horizon, MRK at $112 is a reasonable position with defined risk parameters. For investors with a 5+ year horizon, the post-Keytruda transition quality is the central thesis to monitor every quarter—and Winrevair’s commercial ramp in 2026–2027 will be the clearest leading indicator of success or failure.

This analysis is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Consult a financial professional before making investment decisions.

---

Data sourced from stockanalysis.com (May 2026). Price targets are author estimates based on publicly available data.